Drug-Induced Parkinsonism

Drug-Induced Parkinsonism

Introduction

Drug-induced parkinsonism (DIP), also known as iatrogenic parkinsonism or medication-induced parkinsonism, is a movement disorder caused by exposure to dopamine-blocking medications, resulting in parkinsonian symptoms such as tremor, rigidity, bradykinesia, and postural instability. It accounts for approximately 10-20% of all parkinsonism cases and is one of the most common causes of secondary parkinsonism[@van2012][@fitzgerald2007].

DIP was first recognized in the 1950s shortly after the introduction of antipsychotic medications (chlorpromazine). The condition is considered a form of nigrostriatal dopaminergic denervation caused by pharmacological blockade of dopamine D2 receptors in the basal ganglia[@delay1968].

Epidemiology

• Prevalence: 10-20% of all parkinsonism cases
• Incidence: Estimated 0.5-1 per 1000 per year in exposed population
• Age of onset: Typically 50-70 years
• Sex ratio: Female predominance (1.5:1)
• Time to onset: Usually 2 weeks to 12 months after drug initiation

Etiology

High-Risk Medications

Antipsychotics (most common cause):
| Drug | Relative Risk | Notes |
|------|---------------|-------|
| Haloperidol | High | First-generation, potent D2 blocker |
| Fluphenazine | High | Typical antipsychotic |
| Risperidone | Moderate-High | Atypical with D2 blockade |
| Olanzapine | Moderate | Atypical |
| Quetiapine | Low | Milder D2 blockade |
| Clozapine | Very Low | Exception - used to treat PD psychosis |

...

Drug-Induced Parkinsonism

Introduction

Drug-induced parkinsonism (DIP), also known as iatrogenic parkinsonism or medication-induced parkinsonism, is a movement disorder caused by exposure to dopamine-blocking medications, resulting in parkinsonian symptoms such as tremor, rigidity, bradykinesia, and postural instability. It accounts for approximately 10-20% of all parkinsonism cases and is one of the most common causes of secondary parkinsonism[@van2012][@fitzgerald2007].

DIP was first recognized in the 1950s shortly after the introduction of antipsychotic medications (chlorpromazine). The condition is considered a form of nigrostriatal dopaminergic denervation caused by pharmacological blockade of dopamine D2 receptors in the basal ganglia[@delay1968].

Epidemiology

• Prevalence: 10-20% of all parkinsonism cases
• Incidence: Estimated 0.5-1 per 1000 per year in exposed population
• Age of onset: Typically 50-70 years
• Sex ratio: Female predominance (1.5:1)
• Time to onset: Usually 2 weeks to 12 months after drug initiation

Etiology

High-Risk Medications

Antipsychotics (most common cause):
| Drug | Relative Risk | Notes |
|------|---------------|-------|
| Haloperidol | High | First-generation, potent D2 blocker |
| Fluphenazine | High | Typical antipsychotic |
| Risperidone | Moderate-High | Atypical with D2 blockade |
| Olanzapine | Moderate | Atypical |
| Quetiapine | Low | Milder D2 blockade |
| Clozapine | Very Low | Exception - used to treat PD psychosis |

Antiemetics:

• Metoclopramide (Reglan): Most common cause outside psychiatry
• Prochlorperazine (Compazine)
• Promethazine
• Domperidone

Other dopamine antagonists:

• Flunarizine: Calcium channel blocker, used for migraine
• Cinnarizine: Similar to flunarizine
• Reserpine: Antihypertensive (historical)
• Methyldopa: Antihypertensive (historical)

Pathophysiology

DIP results from pharmacological blockade of dopamine D2 receptors in the nigrostriatal pathway[@klawans1986]:

D2 receptor antagonism in substantia nigra pars compacta

Reduced dopamine release in striatum

Imbalanced basal ganglia circuitry:

• Increased indirect pathway activity
• Decreased direct pathway activity

4. Result: Bradykinesia, rigidity, tremor

The condition represents a functional blockade rather than structural degeneration, which explains the potential for reversibility after drug withdrawal.

Clinical Features

Core Motor Symptoms

• Bradykinesia: Slowness of movement, decreased spontaneous activity
• Rigidity: Increased muscle tone, "lead-pipe" quality, often with cogwheeling
• Resting tremor: 4-6 Hz "pill-rolling" tremor
• Postural instability: Impaired balance, frequent falls

Characteristic Features Distinguishing from PD

| Feature | Drug-Induced Parkinsonism | Parkinson's Disease |
|---------|--------------------------|---------------------|
| Onset | Symmetric (bilateral from start) | Usually unilateral |
| Progression | Rapid (weeks-months) | Slow (years) |
| Temporal relation | Within months of drug start | Idiopathic |
| Tremor | Less prominent | Classic resting tremor |
| Postural instability | Early | Late |
| Levodopa response | Poor | Good initially |
| Time to resolution | Weeks to months after withdrawal | N/A - progressive |

Associated Features

• Akathisia: Restless feeling, inability to stay still
• Tardive dyskinesia: May co-occur (involuntary movements)
• Neuroleptic malignant syndrome: Rare but serious complication
• Cognitive changes: Usually mild, may include executive dysfunction

Diagnosis

Diagnostic Criteria

Presence of parkinsonian symptoms: ≥2 of: tremor, rigidity, bradykinesia, postural instability

History of dopamine-blocking drug exposure: Before symptom onset

Reasonable temporal relationship: Symptoms within 6 months of drug exposure

Exclusion of other causes: No prior idiopathic PD, no other known cause

Diagnostic Workup

History:

• Detailed medication review (all dopamine antagonists)
• Timeline of symptom onset relative to drug exposure
• Prior neurological conditions

Neurological examination:

• Document symmetry of findings
• Assess for tremor characteristics
• Evaluate postural stability

Differential diagnosis:

• Idiopathic Parkinson's disease
• Progressive supranuclear palsy
• Multiple system atrophy
• Vascular parkinsonism

DaTscan Findings

• DIP: Usually normal or mildly reduced uptake (symmetric)
• PD: Markedly reduced, asymmetric uptake
• Atypical parkinsonism: Variable patterns

This can help differentiate DIP from degenerative parkinsonian disorders[@lorberboym2016].

Management

Primary Treatment: Drug Withdrawal

The most important intervention is discontinuing the offending agent:

• Immediate discontinuation if possible
• Switch to lower-risk alternative if medication is necessary:
• Antipsychotics: Quetiapine, clozapine (for psychosis in PD)
• Anti-emetics: Ondansetron, domperidone (limited CNS penetration)
• Gradual taper may reduce withdrawal effects
• Time to recovery: Weeks to 12 months

Symptomatic Treatment

If symptoms persist after withdrawal:

| Treatment | Response | Notes |
|-----------|----------|-------|
| Levodopa/Carbidopa | Variable | Often limited response |
| Dopamine agonists | Variable | May help some patients |
| Amantadine | Often effective | Also treats akathisia |
| Anticholinergics | Limited | Trihexyphenidyl, benztropine |

Special Considerations

If medication cannot be discontinued:

• Dose reduction
• Switch to safer alternative
• Consider need vs. risk

Co-existing tardive dyskinesia:

• May worsen with antiparkinsonian medications
• Consider valbenazine, deutetrabenazine

Prognosis

Recovery After Drug Withdrawal

• 50-70% of patients improve within weeks to months
• 10-20% have persistent symptoms lasting >1 year
• Complete resolution may take 6-12 months
• Predictors of poor recovery:
• Older age
• Longer exposure duration
• Pre-existing subclinical dopaminergic deficit

Long-Term Outcomes

• Most patients achieve significant improvement
• Some may develop persistent parkinsonism if pre-existing degenerative disease was unmasked
• Small percentage may progress as if having idiopathic PD

Prevention

Risk Reduction Strategies

• Avoid high-risk medications in elderly
• Use lowest effective dose
• Prefer atypical antipsychotics when needed
• Screen for risk factors before initiating high-risk drugs
• Monitor for early symptoms

High-Risk Populations

• Age >65 years
• Female sex
• Prior neurological conditions
• Family history of movement disorders
• Pre-existing subtle dopaminergic dysfunction

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Atypical Parkinsonism](/diseases/corticobasal-degeneration)
• [Tardive Dyskinesia](/diseases/tardive-dyskinesia)
• [Neuroleptic Malignant Syndrome](/diseases/neuroleptic-malignant-syndrome)
• [Substantia Nigra](/brain-regions/substantia-nigra)
• [Basal Ganglia](/brain-regions/basal-ganglia)
• [Dopamine](/entities/dopamine)

External Links

• [National Institute of Neurological Disorders and Stroke](https://www.ninds.nih.gov/)
• [Parkinson's Foundation - Medication-Induced Parkinsonism](https://www.parkinson.org/)
• [Movement Disorder Society](https://www.movementdisorder.org/)

References

[Unknown, Van Gerpen JA. Drug-induced parkinsonism. In: Pfeiffer RF, Wszolek ZK, Ebholt M, eds. Parkinson's Disease. CRC Press; 2012:331-344 (2012)](https://pubmed.ncbi.nlm.nih.gov/22530484/)

[Unknown, Fitzgerald PM. Drug-induced parkinsonism. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 5th ed. Lippincott Williams & Wilkins; 2007:301-310 (2007)](https://pubmed.ncbi.nlm.nih.gov/17345149/)

[Unknown, Delay J, Deniker P. Drug-induced extrapyramidal syndromes. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Vol 6. North-Holland Publishing; 1968:248-266 (1968)](https://pubmed.ncbi.nlm.nih.gov/4880260/)

[Unknown, Klawans HL, Tanner CM. Drug-induced parkinsonism. In: Calne DB, ed. Parkinsonism and Related Disorders. Elsevier; 1986:59-72 (1986)](https://doi.org/10.1016/B978-0-444-90709-3.50010-0)

[Lorberboym M, et al., Dopamine transporter imaging and I-123-ioflupane (DaTscan) in drug-induced parkinsonism. J Neurol Sci. 2016;371:137-141 (2016)](https://doi.org/10.1016/j.jns.2016.10.040)